Foreign Drug Inspections Would Be Funded By Registration Fees In Draft U.S. Bill
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA inspections of overseas drug producers would be supported by annual registration fees under a legislative "discussion draft" being circulated by House Energy and Commerce Committee Chairman John Dingell, D-Mich.